These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 32694141)
1. An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease. Aaron PA; Vu K; Gelli A mBio; 2020 Jul; 11(4):. PubMed ID: 32694141 [No Abstract] [Full Text] [Related]
2. Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. Vu K; Tham R; Uhrig JP; Thompson GR; Na Pombejra S; Jamklang M; Bautos JM; Gelli A mBio; 2014 Jun; 5(3):e01101-14. PubMed ID: 24895304 [TBL] [Abstract][Full Text] [Related]
3. Harnessing the Activity of the Fungal Metalloprotease, Mpr1, To Promote Crossing of Nanocarriers through the Blood-Brain Barrier. Aaron PA; Gelli A ACS Infect Dis; 2020 Jan; 6(1):138-149. PubMed ID: 31820926 [No Abstract] [Full Text] [Related]
4. The structure-function analysis of the Mpr1 metalloprotease determinants of activity during migration of fungal cells across the blood-brain barrier. Na Pombejra S; Jamklang M; Uhrig JP; Vu K; Gelli A PLoS One; 2018; 13(8):e0203020. PubMed ID: 30161190 [TBL] [Abstract][Full Text] [Related]
5. The Metalloprotease, Mpr1, Engages AnnexinA2 to Promote the Transcytosis of Fungal Cells across the Blood-Brain Barrier. Na Pombejra S; Salemi M; Phinney BS; Gelli A Front Cell Infect Microbiol; 2017; 7():296. PubMed ID: 28713781 [TBL] [Abstract][Full Text] [Related]
6. Discovery of Simplified Sampangine Derivatives with Potent Antifungal Activities against Cryptococcal Meningitis. Li Z; Liu N; Tu J; Ji C; Han G; Sheng C ACS Infect Dis; 2019 Aug; 5(8):1376-1384. PubMed ID: 31070884 [TBL] [Abstract][Full Text] [Related]
7. Cryptococcal Meningitis and Anti-virulence Therapeutic Strategies. Vu K; Garcia JA; Gelli A Front Microbiol; 2019; 10():353. PubMed ID: 30863389 [TBL] [Abstract][Full Text] [Related]
8. Shaw KJ; Schell WA; Covel J; Duboc G; Giamberardino C; Kapoor M; Moloney M; Soltow QA; Tenor JL; Toffaletti DL; Trzoss M; Webb P; Perfect JR Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891599 [TBL] [Abstract][Full Text] [Related]
9. Cryptococcus neoformans, a global threat to human health. Zhao Y; Ye L; Zhao F; Zhang L; Lu Z; Chu T; Wang S; Liu Z; Sun Y; Chen M; Liao G; Ding C; Xu Y; Liao W; Wang L Infect Dis Poverty; 2023 Mar; 12(1):20. PubMed ID: 36932414 [TBL] [Abstract][Full Text] [Related]
10. Inositol Metabolism Regulates Capsule Structure and Virulence in the Human Pathogen Cryptococcus neoformans. Wang Y; Wear M; Kohli G; Vij R; Giamberardino C; Shah A; Toffaletti DL; Yu CA; Perfect JR; Casadevall A; Xue C mBio; 2021 Dec; 12(6):e0279021. PubMed ID: 34724824 [TBL] [Abstract][Full Text] [Related]
11. Combatting the evolution of antifungal resistance in Cryptococcus neoformans. Bermas A; Geddes-McAlister J Mol Microbiol; 2020 Nov; 114(5):721-734. PubMed ID: 32697029 [TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical and biological characteristics of HIV-infected patients presenting Cryptococcus neoformans versus C. curvatus/C. laurentii meningitis. Zono B; Moutschen M; Situakibanza H; Sacheli R; Muendele G; Kabututu P; Biakabuswa A; Landu N; Mvumbi G; Hayette MP BMC Infect Dis; 2021 Nov; 21(1):1157. PubMed ID: 34781895 [TBL] [Abstract][Full Text] [Related]
14. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Odom A; Del Poeta M; Perfect J; Heitman J Antimicrob Agents Chemother; 1997 Jan; 41(1):156-61. PubMed ID: 8980772 [TBL] [Abstract][Full Text] [Related]
16. Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. Liu TB; Kim JC; Wang Y; Toffaletti DL; Eugenin E; Perfect JR; Kim KJ; Xue C PLoS Pathog; 2013; 9(4):e1003247. PubMed ID: 23592982 [TBL] [Abstract][Full Text] [Related]
17. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Butts A; DiDone L; Koselny K; Baxter BK; Chabrier-Rosello Y; Wellington M; Krysan DJ Eukaryot Cell; 2013 Feb; 12(2):278-87. PubMed ID: 23243064 [TBL] [Abstract][Full Text] [Related]
18. Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. Wambaugh MA; Denham ST; Ayala M; Brammer B; Stonhill MA; Brown JC Elife; 2020 May; 9():. PubMed ID: 32367801 [TBL] [Abstract][Full Text] [Related]